| Title: |
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis |
| Authors: |
Calabrese M.; Preziosa P.; Scalfari A.; Colato E.; Marastoni D.; Absinta M.; Battaglini M.; De Stefano N.; Di Filippo M.; Hametner S.; Howell O. W.; Inglese M.; Lassmann H.; Martin R.; Nicholas R.; Reynolds R.; Rocca M. A.; Tamanti A.; Vercellino M.; Villar L. M.; Filippi M.; Magliozzi R. |
| Contributors: |
Calabrese, M.; Preziosa, P.; Scalfari, A.; Colato, E.; Marastoni, D.; Absinta, M.; Battaglini, M.; De Stefano, N.; Di Filippo, M.; Hametner, S.; Howell, O. W.; Inglese, M.; Lassmann, H.; Martin, R.; Nicholas, R.; Reynolds, R.; Rocca, M. A.; Tamanti, A.; Vercellino, M.; Villar, L. M.; Filippi, M.; Magliozzi, R. |
| Publication Year: |
2024 |
| Collection: |
Università degli Studi di Siena: USiena air |
| Subject Terms: |
Biomarker; Disease Progression; Human; Multiple Sclerosi; Recurrence |
| Description: |
Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a smoldering inflammatory activity is present from the earliest stages of the disease and underlies the progression of disability, which proceeds relentlessly and independently of clinical and radiological relapses (PIRA). The complex system of pathological events driving “chronic” worsening is likely linked with the early accumulation of compartmentalized inflammation within the central nervous system as well as insufficient repair phenomena and mitochondrial failure. These mechanisms are partially lesion-independent and differ from those causing clinical relapses and the formation of new focal demyelinating lesions; they lead to neuroaxonal dysfunction and death, myelin loss, glia alterations, and finally, a neuronal network dysfunction outweighing central nervous system (CNS) compensatory mechanisms. This review aims to provide an overview of the state of the art of neuropathological, immunological, and imaging knowledge about the mechanisms underlying the smoldering disease activity, focusing on possible early biomarkers and their translation into clinical practice. ANN NEUROL 2024;96:1–20. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38568026; info:eu-repo/semantics/altIdentifier/wos/WOS:001196070800001; volume:96; issue:1; firstpage:1; lastpage:20; numberofpages:20; journal:ANNALS OF NEUROLOGY; https://hdl.handle.net/11365/1282455 |
| DOI: |
10.1002/ana.26913 |
| Availability: |
https://hdl.handle.net/11365/1282455; https://doi.org/10.1002/ana.26913; https://onlinelibrary.wiley.com/doi/10.1002/ana.26913 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.4BBD7B4E |
| Database: |
BASE |